Dr. Reddy's Lab shares climb 3% on signing exclusive agreement to distribute dengue vaccine in India

This comes as the pharmaceutical company entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Ltd for Qdenga in the private market in India.

At around 2:13 PM, the stock was trading 1.23% higher at ₹1,189.50 per equity share. The scrip has advanced 2% in the past week and nearly 1% over the month. However, on a year-to-date (YTD) basis, it has fallen 5%.

According to a regulatory filing, Qdenga is a dengue vaccine developed by Takeda to protect against all four dengue virus serotypes.

Under the terms of the agreement, Dr. Reddy’s will be exclusively responsible for distribution and marketing of Qdenga in the Indian private market, while Takeda will retain commercialisation rights in the Indian public market and will be responsible for manufacturing and importation of the vaccine.

Dr Reddy’s gets voluntary license for Gilead’s once-yearly HIV prevention drug

In a separate press release dated September 17, the company said that it has received a royalty-free, non-exclusive voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP).

The agreement builds on Dr. Reddy's existing voluntary licensing arrangement with Gilead, signed in October 2024, for twice-yearly lenacapavir for HIV prevention.

The agreement aims to facilitate manufacturing readiness, technology transfer and future supply planning for investigational once-yearly lenacapavir while clinical development efforts continue in the licensed territories, primarily low- and lower-middle-income countries.

“The collaboration further strengthens Dr. Reddy's Public Health Access portfolio, which focuses on improving access to medicines across communicable diseases, reproductive health, and maternal and child health. HIV continues to represent a significant global public health challenge, underscoring the need for innovative long-acting prevention options,” it stated.

The company added that the investigational once-yearly lenacapavir is currently being evaluated in Gilead's ongoing Phase 3 PURPOSE 365 study.

“Once-yearly lenacapavir for HIV prevention is investigational and has not been approved by any regulatory authority. Its safety and efficacy have not been established,” it added.

Dr. Reddy’s Q1 results

Dr. Reddy's Laboratories reported a consolidated net profit (attributable to the owners of the company) of ₹443.5 crore in the first quarter of the 2026-27 financial year (Q1 FY27), reflecting a 68.72% year-on-year (YoY) fall from ₹1,417.8 crore in the year-ago period.

Its results recorded an adverse impact of a provision of ₹239.7 crore towards inventory and other associated costs related to semaglutide's active pharmaceutical ingredient (semaglutide APi related impact), resulting in a decrease in gross profit, EBITDA (earnings before interest, tax, depreciation and amortisation) and PBT (profit before tax) margins by approximately 3%.

Its revenue from operations declined by 5.55% YoY to ₹8,070.5 crore for the reporting quarter, from ₹8,545.2 crore in Q1 FY26.

Dr. Reddy's Laboratories has a total market capitalisation of ₹99,201.71 crore as of September 18, 2026, according to data on the NSE.